Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Can We Understand It Better

《Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Can We Understand It Better》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、VOLUME34•NUMBER6•FEBRUARY20,2016JOURNALOFCLINICALONCOLOGYEDITORIALLookingDeepIntotheHeterogeneityofHumanEpidermalGrowthFactorReceptor2–PositiveBreastCancer:CanWeUnderstandItBetter?ShereneLoiandPeterSavas,PeterMacCallumCancerCentre,EastMelbourne,Victoria,Au

2、straliaSeeaccompanyingarticleonpage542Thesuccessoftrastuzumabwhencombinedwithcytotoxicpoint,withallthebenefitsofrandomizedassignment,completeclinicalchemotherapytoalterthepreviouslyaggressivenaturalhistoryofannotation,andconsistenttreatmentadministration.Co

3、rrelativehumanepidermalgrowthfactorreceptor2(HER2)–positivediseasebiomarkerresultsfromaclinicaltrialaremorelikelytoberobust3hasbeenremarkable.Despiteintensiveresearch,understandingtheandreproducibleforthesereasons.2biologicfactorsthatleadtoresistanceinsome

4、patientsandtheInthestudybyCareyetal,thetrastuzumabandlapatinibintegrationofsuchfactorsintotheclinicalsettinghasbeenslow.combinationarmproducedanumericallyhigherbutnotstatisticallyTherelevanceofestrogenreceptor(ER)signalingintermsofre-significantincreaseinth

5、eratesofpCRinthebreast,whichwasthesponseintheneoadjuvantsettingandprognosisintheadjuvantprimaryendpointofthestudy.Thetrastuzumab-alonecontrolarmwassettingisrecognizedbutdoesnotyetinfluencethewaywemanageobservedtohaveahigherpCRraterelativetothatinothercompar

6、able4,5anti-HER2therapy.Theidentificationofbothprognosticandpre-studies.Thismaybepartlyexplainedbytheinclusionofsmallerdictivefactorsbecomesparticularlycriticalasweseemtobemovingtumors($1cm).Notably,however,only64%ofpatientsintheintoaneraofdualanti-HER2ther

7、apy.TheCancerGenomeAtlaslapatinibarmand85%inthecombinationarm(evenafterlapatinibsubjected510primarybreasttumorstomutation,transcript,copydosereduction)comparedwith92%inthecontrolarmcompletednumber,methylation,andproteinanalyses.Only50%ofclinicaltheentirepr

8、otocol-specifiedneoadjuvanttherapy,whichmayhaveHER2-positivetumorswerecharacterizedasHER2enrichedatthecontributedtothelackofstatisticalsignificanceforthecombinationmRNAandproteinlevel,andtherestwerepredominantl